126 related articles for article (PubMed ID: 24900471)
1. Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives as Inhibitors of Complement.
Zhang M; Yang XY; Tang W; Groeneveld TW; He PL; Zhu FH; Li J; Lu W; Blom AM; Zuo JP; Nan FJ
ACS Med Chem Lett; 2012 Apr; 3(4):317-21. PubMed ID: 24900471
[TBL] [Abstract][Full Text] [Related]
2. Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel.
Zhang HZ; Xu XL; Chen HY; Ali S; Wang D; Yu JW; Xu T; Nan FJ
Acta Pharmacol Sin; 2015 Sep; 36(9):1137-44. PubMed ID: 26256403
[TBL] [Abstract][Full Text] [Related]
3. Molecular hybrids of substituted phenylcarbamoylpiperidine and 1,2,4-triazole methylacetamide as potent 15-LOX inhibitors: Design, synthesis, DFT calculations and molecular docking studies.
Nawaz Z; Riaz N; Saleem M; Iqbal A; Abida Ejaz S; Bashir B; Muzaffar S; Ashraf M; Aziz-Ur-Rehman ; Sajjad Bilal M; Krishna Prabhala B; Sajid S
Bioorg Chem; 2024 Feb; 143():106984. PubMed ID: 38056389
[TBL] [Abstract][Full Text] [Related]
4. A novel ELISA for the evaluation of the classical pathway of complement.
Zwirner J; Wittig A; Kremmer E; Götze O
J Immunol Methods; 1998 Feb; 211(1-2):183-90. PubMed ID: 9617842
[TBL] [Abstract][Full Text] [Related]
5. Probing phenylcarbamoylazinane-1,2,4-triazole amides derivatives as lipoxygenase inhibitors along with cytotoxic, ADME and molecular docking studies.
Muzaffar S; Shahid W; Riaz N; Saleem M; Ashraf M; Aziz-Ur-Rehman ; Bashir B; Kaleem A; Al-Rashida M; Baral B; Bhattarai K; Gross H
Bioorg Chem; 2021 Feb; 107():104525. PubMed ID: 33317840
[TBL] [Abstract][Full Text] [Related]
6. Novel 2-oxo-2-phenylethoxy and benzyloxy diaryl urea hybrids as VEGFR-2 inhibitors: Design, synthesis, and anticancer evaluation.
Ghannam IAY; El Kerdawy AM; Mounier MM; Abo-Elfadl MT; Ali IH
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200341. PubMed ID: 36398495
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Potent EGFR Inhibitors With
Li M; Xue N; Liu X; Wang Q; Yan H; Liu Y; Wang L; Shi X; Cao D; Zhang K; Zhang Y
Front Pharmacol; 2021; 12():647591. PubMed ID: 34122069
[TBL] [Abstract][Full Text] [Related]
8. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues.
Mostert S; Mentz W; Petzer A; Bergh JJ; Petzer JP
Bioorg Med Chem; 2012 Dec; 20(24):7040-50. PubMed ID: 23122934
[TBL] [Abstract][Full Text] [Related]
10. Novel coumarin-chalcone derivatives: Synthesis, characterization, antioxidant, cyclic voltammetry, molecular modelling and biological evaluation studies as acetylcholinesterase, α-glycosidase, and carbonic anhydrase inhibitors.
Çelik Onar H; Özden EM; Taslak HD; Gülçin İ; Ece A; Erçağ E
Chem Biol Interact; 2023 Sep; 383():110655. PubMed ID: 37573926
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2,4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors.
Li R; Gong L; Sun J; Liang Z; He J; Huang J; Ning X; Song H; Li R; Zhang Q; Lin Z; Yin Y
Bioorg Chem; 2024 Mar; 144():107134. PubMed ID: 38237389
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents.
Qi H; Chen L; Liu B; Wang X; Long L; Liu D
Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902
[TBL] [Abstract][Full Text] [Related]
13. Arylmethylene hydrazine derivatives containing 1,3-dimethylbarbituric moiety as novel urease inhibitors.
Pedrood K; Azizian H; Montazer MN; Mohammadi-Khanaposhtani M; Asgari MS; Asadi M; Bahadorikhalili S; Rastegar H; Larijani B; Amanlou M; Mahdavi M
Sci Rep; 2021 May; 11(1):10607. PubMed ID: 34012008
[TBL] [Abstract][Full Text] [Related]
14. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
15. An Efficient Synthesis of 1-(1,3-Dioxoisoindolin-2-yl)-3-aryl Urea Analogs as Anticancer and Antioxidant Agents: An Insight into Experimental and
Afzal O; Ahsan MJ
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202650
[TBL] [Abstract][Full Text] [Related]
16. Novel 5-(Arylideneamino)-1
Ali S; Ali M; Khan A; Ullah S; Waqas M; Al-Harrasi A; Latif A; Ahmad M; Saadiq M
ACS Omega; 2022 Dec; 7(48):43468-43479. PubMed ID: 36506132
[TBL] [Abstract][Full Text] [Related]
17. Shark complement: an assessment.
Smith SL
Immunol Rev; 1998 Dec; 166():67-78. PubMed ID: 9914903
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy.
Zeng WB; Ji TY; Zhang YT; Ma YF; Li R; You WW; Zhao PL
Bioorg Chem; 2024 Feb; 143():107019. PubMed ID: 38096683
[TBL] [Abstract][Full Text] [Related]
19. Conjugates of podophyllotoxin and norcantharidin as dual inhibitors of topoisomeraseⅡ and protein phosphatase 2A.
Tang ZB; Chen YZ; Zhao J; Guan XW; Bo YX; Chen SW; Hui L
Eur J Med Chem; 2016 Nov; 123():568-576. PubMed ID: 27517805
[TBL] [Abstract][Full Text] [Related]
20. The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase.
Woehl JL; Stapels DAC; Garcia BL; Ramyar KX; Keightley A; Ruyken M; Syriga M; Sfyroera G; Weber AB; Zolkiewski M; Ricklin D; Lambris JD; Rooijakkers SHM; Geisbrecht BV
J Immunol; 2014 Dec; 193(12):6161-6171. PubMed ID: 25381436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
